All In Biotech

Drug Trial Radar · NCT04261075

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Mar 3, 2020

Primary completion

Jun 16, 2022

Study completion Jun 16, 2022

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 101 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • IPH5201Biological

    Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

  • durvalumabBiological

    Durvalumab Q3W for a maximum of 2 years

  • oleclumabBiological

    Oleclumab Q3W for a maximum of 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events as a measure of safetyTime frame: From time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months
  2. Incidence of clinically significant laboratory values as a measure of safetyTime frame: From time of informed consent through 12 weeks after the last dose of investigational product, approximately 7 months
  3. Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safetyTime frame: From time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntersville, North Carolina

  • Research Site

    Providence, Rhode Island

  • Research Site

    Nashville, Tennessee

  • Research Site

    Bordeaux, France

  • Research Site

    Villejuif, France

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Lausanne, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.